2005
DOI: 10.1016/j.jconrel.2004.07.021
|View full text |Cite
|
Sign up to set email alerts
|

A biomedical library of serinol-derived polyesters

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
7
0

Year Published

2005
2005
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 27 publications
0
7
0
Order By: Relevance
“…[ 2 ] Accordingly, it is now possible to construct new materials with a large range of physicochemical properties and, of significant importance, from building blocks which are either already in clinical use, [ 3 ] or which have relatively low barriers to translation. [ 4 ] However, for diseases including many cancers, there remain multiple unknowns concerning how such new materials might overcome the key barriers to drug delivery, namely, the ability to concentrate a therapeutic agent in a target site in sufficient dose and for sufficient time to afford an efficacious response. The potential advantages of polymer pro‐drugs are that they can be designed to release drugs either at a controlled rate in plasma to ensure drug concentrations remain in the therapeutic window, or they can be encoded with functionality to ensure that release only occurs in the disease site.…”
Section: Introductionmentioning
confidence: 99%
“…[ 2 ] Accordingly, it is now possible to construct new materials with a large range of physicochemical properties and, of significant importance, from building blocks which are either already in clinical use, [ 3 ] or which have relatively low barriers to translation. [ 4 ] However, for diseases including many cancers, there remain multiple unknowns concerning how such new materials might overcome the key barriers to drug delivery, namely, the ability to concentrate a therapeutic agent in a target site in sufficient dose and for sufficient time to afford an efficacious response. The potential advantages of polymer pro‐drugs are that they can be designed to release drugs either at a controlled rate in plasma to ensure drug concentrations remain in the therapeutic window, or they can be encoded with functionality to ensure that release only occurs in the disease site.…”
Section: Introductionmentioning
confidence: 99%
“…The –OH groups can react with the diisocyanate and the –NH 2 group can be protected for further biofunctioanlization. Equally important is the biocompatibility of serinol [28, 29]. We chose hexamethylene diisocyanate (HDI) because it has been used in many polyurethanes [3033].…”
Section: Introductionmentioning
confidence: 99%
“…Serinol was selected for the polymer synthesis because of its proven biocompatibility as a monomer for biodegradable polyesters. 13 A coupling reaction between TMBQ-succinimidyl ester and serinol consequently yielded a diol with a pendant TMBQ (compound 1). Synthesized serinol monomer was successfully confirmed by 1 H and 13 C NMR spectroscopy and elemental analysis.…”
mentioning
confidence: 99%
“…13 A coupling reaction between TMBQ-succinimidyl ester and serinol consequently yielded a diol with a pendant TMBQ (compound 1). Synthesized serinol monomer was successfully confirmed by 1 H and 13 C NMR spectroscopy and elemental analysis. The serinol monomer was polymerized by the reaction described in Scheme 2.…”
mentioning
confidence: 99%